阿尔茨海默病中利培酮更安全处方的药代动力学研究
该分析利用CATIE-AD研究数据(n=108),构建利培酮与9-OH-利培酮的药代动力学模型,发现利培酮清除率随年龄下降(P<0.0001),9-OH-利培酮消除半衰期27小时,22%患者活性部分清除较慢。较高的9-OH-利培酮谷浓度和活性部分浓度(P<0.0001)及较低MMSE评分(P<0.0001)与EPS相关。模型预测最佳剂量从0.25 mg/天(85岁,MMSE 5)到1 mg/天(75岁,MMSE 15),清除较慢者需隔日给药。
要点
- 利培酮清除率随年龄增长而下降,9-OH-利培酮半衰期约27小时。
- 较高9-OH-利培酮谷浓度和活性部分浓度及较低MMSE评分与EPS相关。
- 模型预测最佳剂量随年龄和MMSE评分调整,清除慢者需隔日给药。
核心结论
- 研究结果支持根据年龄和MMSE评分调整利培酮剂量,并提示可用单次浓度-剂量比识别清除较慢的患者。
研究设计与样本
- 基于CATIE-AD研究(NCT00015548)数据的药代动力学建模与逻辑回归分析,共纳入108名参与者。
主要发现
- 模型显示利培酮清除率随年龄相关下降(P<0.0001)。
- 9-OH-利培酮肾脏消除减少,消除半衰期为27小时。
- 22%患者活性部分清除较慢,浓度-剂量比为20.2(s.d.=7.2)对7.6(s.d.=4.9)ng/mL per mg/day(Mann-Whitney U检验,P<0.0001)。
- 较高的9-OH-利培酮谷浓度和活性部分浓度(P<0.0001)及较低MMSE评分(P<0.0001)与EPS相关。
关键数值与推荐
- 模型预测最佳剂量范围从0.25 mg/天(85岁,MMSE 5)到1 mg/天(75岁,MMSE 15)。
- 清除较慢者需隔日给药。
临床怎么用
- 临床处方利培酮时应考虑年龄和MMSE评分进行剂量调整。
- 可考虑使用浓度-剂量比识别清除较慢的患者以指导给药间隔。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the treatment of psychosis, agitation and aggression in Alzheimer's disease, guidelines emphasise the need to 'use the lowest possible dose' of antipsychotic drugs, but provide no information on optimal dosing. AIMS: This analysis investigated the pharmacokinetic profiles of risperidone and 9-hydroxy (OH)-risperidone, and how these related to treatment-emergent extrapyramidal side-effects (EPS), using data from The Clinical Antipsychotic Trials of Intervention Effectiveness in Alzheimer's Disease study (Clinicaltrials.gov identifier: NCT00015548). METHOD: A statistical model, which described the concentration-time course of risperidone and 9-OH-risperidone, was used to predict peak, trough and average concentrations of risperidone, 9-OH-risperidone and 'active moiety' (combined concentrations) (n = 108 participants). Logistic regression was used to investigate the associations of pharmacokinetic biomarkers with EPS. Model-based predictions were used to simulate the dose adjustments needed to avoid EPS. RESULTS: The model showed an age-related reduction in risperidone clearance (P < 0.0001), reduced renal elimination of 9-OH-risperidone (elimination half-life 27 h), and slower active moiety clearance in 22% of patients, (concentration-to-dose ratio: 20.2 (s.d. = 7.2) v. 7.6 (s.d. = 4.9) ng/mL per mg/day, Mann-Whitney U-test, P < 0.0001). Higher trough 9-OH-risperidone and active moiety concentrations (P < 0.0001) and lower Mini-Mental State Examination (MMSE) scores (P < 0.0001), were associated with EPS. Model-based predictions suggest the optimum dose ranged from 0.25 mg/day (85 years, MMSE of 5), to 1 mg/day (75 years, MMSE of 15), with alternate day dosing required for those with slower drug clearance. CONCLUSIONS: Our findings argue for age- and MMSE-related dose adjustments and suggest that a single measure of the concentration-to-dose ratio could be used to identify those with slower drug clearance.
引用
- Reeves S, Bertrand J, Uchida H, et al. Towards safer risperidone prescribing in Alzheimer's disease. Br J Psychiatry. 2021. PMID: 33176899. doi:10.1192/bjp.2020.225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。